TY - JOUR
T1 - Telemedicine for diabetes management during COVID-19
T2 - what we have learnt, what and how to implement
AU - The CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO)
AU - Rosta, Laszlo
AU - Menyhart, Adrienn
AU - Mahmeed, Wael Al
AU - Al-Rasadi, Khalid
AU - Al-Alawi, Kamila
AU - Banach, Maciej
AU - Banerjee, Yajnavalka
AU - Ceriello, Antonio
AU - Cesur, Mustafa
AU - Cosentino, Francesco
AU - Firenze, Alberto
AU - Galia, Massimo
AU - Goh, Su Yen
AU - Janez, Andrej
AU - Kalra, Sanjay
AU - Kapoor, Nitin
AU - Lessan, Nader
AU - Lotufo, Paulo
AU - Papanas, Nikolaos
AU - Rizvi, Ali A.
AU - Sahebkar, Amirhossein
AU - Santos, Raul D.
AU - Stoian, Anca Pantea
AU - Toth, Peter P.
AU - Viswanathan, Vijay
AU - Kempler, Peter
AU - Rizzo, Manfredi
N1 - Copyright © 2023 Rosta, Menyhart, Mahmeed, Al-Rasadi, Al-Alawi, Banach, Banerjee, Ceriello, Cesur, Cosentino, Firenze, Galia, Goh, Janez, Kalra, Kapoor, Lessan, Lotufo, Papanas, Rizvi, Sahebkar, Santos, Stoian, Toth, Viswanathan, Kempler and Rizzo.
PY - 2023/5/17
Y1 - 2023/5/17
N2 - The past two decades have witnessed telemedicine becoming a crucial part of health care as a method to facilitate doctor-patient interaction. Due to technological developments and the incremental acquisition of experience in its use, telemedicine’s advantages and cost-effectiveness has led to it being recognised as specifically relevant to diabetology. However, the pandemic created new challenges for healthcare systems and the rate of development of digital services started to grow exponentially. It was soon discovered that COVID-19-infected patients with diabetes had an increased risk of both mortality and debilitating sequelae. In addition, it was observed that this higher risk could be attenuated primarily by maintaining optimal control of the patient’s glucose metabolism. As opportunities for actual physical doctor-patient visits became restricted, telemedicine provided the most convenient opportunity to communicate with patients and maintain delivery of care. The wide range of experiences of health care provision during the pandemic has led to the development of several excellent strategies regarding the applicability of telemedicine across the whole spectrum of diabetes care. The continuation of these strategies is likely to benefit clinical practice even after the pandemic crisis is over.
AB - The past two decades have witnessed telemedicine becoming a crucial part of health care as a method to facilitate doctor-patient interaction. Due to technological developments and the incremental acquisition of experience in its use, telemedicine’s advantages and cost-effectiveness has led to it being recognised as specifically relevant to diabetology. However, the pandemic created new challenges for healthcare systems and the rate of development of digital services started to grow exponentially. It was soon discovered that COVID-19-infected patients with diabetes had an increased risk of both mortality and debilitating sequelae. In addition, it was observed that this higher risk could be attenuated primarily by maintaining optimal control of the patient’s glucose metabolism. As opportunities for actual physical doctor-patient visits became restricted, telemedicine provided the most convenient opportunity to communicate with patients and maintain delivery of care. The wide range of experiences of health care provision during the pandemic has led to the development of several excellent strategies regarding the applicability of telemedicine across the whole spectrum of diabetes care. The continuation of these strategies is likely to benefit clinical practice even after the pandemic crisis is over.
KW - COVID - 19
KW - diabetes care
KW - diabetes prevention and control
KW - glucose monitoring
KW - telemedicine
KW - type-2 diabetes (T2DM)
KW - Diabetes Mellitus/epidemiology
KW - COVID-19/epidemiology
KW - Telemedicine
KW - Delivery of Health Care
KW - Humans
UR - http://www.scopus.com/inward/record.url?scp=85161113246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161113246&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/f8ae451e-d5e5-3572-bac5-7600b2469b88/
U2 - 10.3389/fendo.2023.1129793
DO - 10.3389/fendo.2023.1129793
M3 - Review article
C2 - 37265696
AN - SCOPUS:85161113246
SN - 1664-2392
VL - 14
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1129793
ER -